The stocks with the worst fall in pharmaceutical stocks

As for the stocks with the worst fall in pharmaceutical stocks, this article will focus on the stocks with the worst fall in pharmaceutical stocks and the stocks that have not risen in pharmaceutical stocks. Stocks, stocks with polarized pharmaceutical stocks, stocks with soaring pharmaceutical stocks, stocks with low-priced pharmaceutical stocks and high dividends will be answered and discussed. I hope it will be helpful to you.

The worst-falling pharmaceutical stock

One of the worst-falling pharmaceutical stocks is Meikang Biologics (300439). As of the close of trading on January 31, 2023, the stock price of Meikang Biological (300439) was 14.48 yuan, a decrease of 9.95. In addition, the stock prices of BGI (300176) and Mingde Biologics (002932) also fell by 17.27 and 16.69 respectively.

The above information is for reference only. Investment is risky and decisions should be made with caution.

Stocks whose pharmaceutical stocks are not rising

The following are some pharmaceutical stocks that have performed poorly recently:

__Baiyunshan (600332): This stock has been underperforming since 2022 It started to fall on August 22, 2018 and has not yet rebounded. The stock price has fallen by a total of 46.53 points.

__WuXi AppTec (02350): The stock began to fall on August 10, 2022, and has not yet rebounded. The stock price has fallen by a total of 44.35.

__Hengrui Medicine (600612): The stock has been falling since August 20, 2022, and has not rebounded yet. The stock price has fallen by 41.43 points.

__Zhifei Biotechnology (300122): The stock began to fall on August 18, 2022, and has not yet rebounded. The stock price has fallen by 39.16 points.

__Mindray Medical (300760): The stock has been falling since August 18, 2022, and has not yet rebounded. The stock price has fallen by 38.96.

The pharmaceutical stocks listed above have performed poorly recently, and investors should fully consider risk factors when making investment decisions.

Stocks with polarization in pharmaceutical stocks

Stocks with polarization in pharmaceutical stocks include:

1. Recovery category: This type of stocks includes pharmaceutical business stocks and Chinese medicine stocks. The trend of pharmaceutical business stocks was strong, while the performance of traditional Chinese medicine stocks was relatively weak.

2. Innovative drugs: The trend of this type of stocks is strong, especially the listed companies of innovative drugs, such as Fosun Pharmaceutical, Livzon Group, Changchun High-tech, Kangtai Biotech, etc.

3. Vaccines: The trend of this type of stocks is also relatively strong, such as Zhifei Biological, Wanbangda, Changhong Huayi, Shanhe Pharmaceutical, Tonghua Jinma, Southwest Synthetic, Tiantan Bio, Lan Bio, and Neptune. Biology, Kehua Biotechnology, Tianli High-tech, Jiaotong University All-in-one, Tibet Pharmaceuticals, Yaozhun Co., Ltd., Haichuang Pharmaceuticals, Yaoshi Technology, Pharmaron Chemicals, etc.

In addition, stocks such as Xinhua Pharmaceutical, Hualan Biotech, Triumph New Materials, Kangtai Biotech, Wantai Biotech, Anke Biotech, Jinlongyu, Zhichunjiang Net Energy, Teyi Pharmaceutical 002727, Renfu Technology 600790, etc. Also performs well. In a research report on the pharmaceutical industry, a number of pharmaceutical stocks were rated as mid-line attention stocks, including Hualan Biotech 002007, Rhine Biotech 002144, Qianjin Pharmaceutical 600479, Tonghua Jinma 000766, Joincare 600657, Harbin Pharmaceutical Group 600664, Jiangsu Pharmaceutical Group Co., Ltd. Traditional Chinese Medicine 600750, Zhendong Pharmaceutical 603488, Xinlitai 002384, Pien Tze Huang 600436, Yunnan Baiyao 000538, Dong'e Ejiao 000423, Jiuzhitang 000969, Tasly 600535, Laobaigan Wine 600559, etc.

Investment is risky and decisions need to be made with caution. It is recommended that you consult a professional investment advisor before carrying out specific operations.

Pharmaceutical stocks soared

On July 13, pharmaceutical stocks soared, including Medicilon, Kangtai Medical, Aohua Endoscopy, Kangtai Medical, iPeng Medical, and American Medical. Dixi, Aohua Endoscopy, iPeng Medical, Mindray Medical, Yao Shi Technology, Medicilon, Kangtai Medical, iPeng Medical, Aohua Endoscopy, Mindray Medical, Yao Shi Technology, Medicilon, Kangtai Medical, iPeng Medical , Aohua Endoscopy, Mindray Medical, Yaoshi Technology, Medicilon, and Kangtai Medical hit their daily limit, Yaoshi Technology rose by more than 17, iPeng Medical rose by more than 15, Xinmai Medical and Xinmai Medical rose by more than 14, and Medicilon rose by more than 13 , Zhaoyan New Drug rose by more than 12, Wenjian Medical and Baicheng Pharmaceutical rose by more than 11, Tigermed and Jindic rose by more than 10, Humanwell Pharmaceuticals, Minova, Pharmaron Chemical, Jiuzhou Pharmaceutical, and Aileen rose by more than 9 , Innovative Medical and Mind Medical rose by more than 8, Shangrong Medical and Lanwei Medical rose by more than 7, and BGI and Minde Biotech rose by more than 6.

There were 20 stocks with an increase of more than 6%. The total trading volume of A-shares was 124.048 billion shares, the turnover was 155.492 billion yuan, and the turnover rate was 2.17.

Pharmaceutical stocks are low-priced and high-dividend stocks.

Pharmaceutical stocks are low-priced and high-dividend stocks. Examples are as follows:

______Hengrui Medicine. ____The company is the largest anti-tumor drug R&D enterprise in China. It has strong R&D capabilities in the field of oncology and has formed a full industrial chain layout from R&D to marketing. Hengrui Medicine's dividend plan for 2022 is 2.5 yuan per 10 shares, with a total dividend of 6.105 billion yuan.

______Changchun High-tech. ____The company is one of the leaders in growth hormone in China. Its product indications cover children, adolescents, adults with growth hormone deficiency, chronic diseases, and patients with burns, trauma, fractures and other stress ulcers who need healing-related bone growth and granulation tissue formation. and many other indications. The 2022 Changchun High-tech dividend plan is 10 yuan per 10, with a total dividend of 4.629 billion yuan.

______AIER Ophthalmology. ____The company is one of the largest ophthalmic medical institutions in China and the largest ophthalmic medical beauty institution in the world. Its ophthalmic medical equipment and medical technology are at the international leading level, and it is a leading enterprise in the field of refractive eye surgery in the world. The dividend plan of Aier Eye Hospital in 2022 is RMB 6 per ten, with a total dividend of RMB 4.563 billion.

______Meinian Health. ____The company is one of the largest chain medical diagnostic service providers in my country. Through a diversified service network covering public hospitals, community centers, high-end physical examination clubs and business exhibitions, it provides a full range of medical services to people of all ages. Diagnostic Comprehensive Services. Meinian Health's dividend plan for 2022 is 1.6 yuan per 10 shares, with a total dividend of 3.469 billion yuan.

______Lepu Medical. ____The company is one of the earliest domestic enterprises engaged in the research, development and production of cardiovascular interventional diagnostic and treatment equipment. Its products cover the three major fields of cardiovascular diagnosis and treatment equipment and equipment, implantable medical devices and in vitro diagnostic reagents and instruments. Lepu Medical's dividend plan for 2022 is 2 yuan per 10, with a total dividend of 3.439 billion yuan.

The above are just some of the pharmaceutical stocks with low prices and high dividends. Investors need to combine more data and information to evaluate investment risks when making choices.

This is the introduction of the stocks with the worst decline in pharmaceutical stocks.